Scientific Expertise

Flow cytometry is a very powerful and reliable alternative to many other methods used for clinical drug development. Consider that it can simultaneously measure multiple parameters on tens of thousands of cells, with a resolution down to a single cell level, robustly and rapidly (greater than 1000 samples per day).

Check out the latest BioPharma Services newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Check out the latest BioPharma Services newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Click here to check out the Bioanalysis ZONE podcast on T-cell immunity monitoring and assay development, featuring Steven Kleiboeker, PhD, our VP of Research & Development at Eurofins Viracor BioPharma.

A global pharmaceutical company partnered with Eurofins Viracor BioPharma to conduct immunogenicity testing for a new vaccine candidate. Eurofins Viracor BioPharma provided specialized expertise and developed precise, robust, and sensitive assays to support the sponsor's clinical trial needs.

Emerging immunotherapies like cancer vaccines and oncolytic viruses show promise for treating cancer. Oncolytic virus therapies face challenges with virus neutralization and clearance. This case study explores methods to characterize the biodistribution and transmissibility of an oncolytic virus candidate in a clinical trial.

Aug 31

P030: Development of a qPCR Assay for HHV-7 Monitoring

Presented By Manisha Diaz

A global pharmaceutical company conducted a European Phase I/IIa clinical study using a flow cytometry-based receptor occupancy (RO) assay to assess drug binding to target cells. The study required assay validation, monitoring, and timely sample analysis. QA-audited data were needed after each cohort for dose escalation decisions.

Eurofins Bioanalytical Services developed a Fit-for-Purpose validation assay for analyzing frozen PBMC samples in a clinical study assessing an intradermal peptide vaccine with checkpoint inhibitors in advanced solid tumor patients. They identified and quantified activated WT1-restricted CD8+ cytotoxic T lymphocytes using immuno-phenotyping and MHC tetramer reagents, and generated CTLs as process QCs for method qualification and sample analysis.